Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Angiogenesis inhibitors.
Das M, Wakelee H. Das M, et al. Among authors: wakelee h. J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S397-8. doi: 10.1097/JTO.0b013e31826df227. J Thorac Oncol. 2012. PMID: 23160332 Free article. Review. No abstract available.
Vascular endothelial growth factor pathway.
Krupitskaya Y, Wakelee H. Krupitskaya Y, et al. Among authors: wakelee h. J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1071-3. doi: 10.1097/01.JTO.0000361755.32660.a1. J Thorac Oncol. 2009. PMID: 19861922 Free article. No abstract available.
Marked tumor response and fatal hemoptysis during radiation for lung cancer in a human immunodeficiency virus-positive patient taking nelfinavir.
Chapman CH, Shen J, Filion EJ, Tran PT, Hara W, Asuncion A, Marko D, Wakelee H, Berry GJ, Dimmick KW, Loo BW Jr, Green J. Chapman CH, et al. Among authors: wakelee h. J Thorac Oncol. 2009 Dec;4(12):1587-9. doi: 10.1097/JTO.0b013e3181bf111d. J Thorac Oncol. 2009. PMID: 20009915 Free article. No abstract available.
Vascular disrupting agents.
Das M, Wakelee H. Das M, et al. Among authors: wakelee h. J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S482-3. doi: 10.1097/01.JTO.0000391376.09556.d8. J Thorac Oncol. 2010. PMID: 21102249 Free article. No abstract available.
Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.
Das M, Donington JS, Murphy J, Kozak M, Eclov N, Whyte RI, Hoang CD, Zhou L, Le QT, Loo BW, Wakelee H. Das M, et al. Among authors: wakelee h. Clin Lung Cancer. 2011 Sep;12(5):280-5. doi: 10.1016/j.cllc.2011.06.003. Epub 2011 Jul 14. Clin Lung Cancer. 2011. PMID: 21752720 Clinical Trial.
Angiogenesis inhibitors.
Das M, Wakelee H. Das M, et al. Among authors: wakelee h. J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1801-2. doi: 10.1097/01.JTO.0000407564.91781.ab. J Thorac Oncol. 2011. PMID: 22005536 Free article. No abstract available.
Targeting VEGF in lung cancer.
Das M, Wakelee H. Das M, et al. Among authors: wakelee h. Expert Opin Ther Targets. 2012 Apr;16(4):395-406. doi: 10.1517/14728222.2012.669752. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22439677 Review.
ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, Nieva JJ, Wakelee HA, Bruce RH. Das M, et al. Among authors: wakelee ha. Lung Cancer. 2012 Aug;77(2):421-6. doi: 10.1016/j.lungcan.2012.04.005. Epub 2012 May 1. Lung Cancer. 2012. PMID: 22555222
344 results